Literature DB >> 17852105

Survival of patients with glioblastoma multiforme has not improved between 1993 and 2004: analysis of 625 cases.

M J Tait1, V Petrik, A Loosemore, B A Bell, M C Papadopoulos.   

Abstract

Glioblastoma is the most common primary brain tumour. The aim of this study was to determine trends in survival over a 12-year period. Survival data were collected retrospectively for 625 patients who had surgery for histologically-confirmed glioblastoma between 1993 and 2004 in a single centre. Data including age, sex, preoperative Karnofsky performance score, tumour site, date of surgery, and type of surgical and adjuvant treatment were collected. Overall median survival was 189 days; there was no significant change in survival over 12 years. Multivariate analysis identified the following independent positive prognostic factors: age <60 years (p < 0.0005), Karnofsky score > or = 70 (p < 0.0001), tumour debulking, rather than biopsy (p < 0.001), right-sided lesion (p < 0.05), unilateral tumour (p < 0.05) and radiotherapy (p < 0.0001). Despite neurosurgical advances, the survival of patients with glioblastoma has not changed for more than a decade. Although, overall, glioblastoma has a short survival, our data show that individual patient survival is heterogeneous.

Entities:  

Mesh:

Year:  2007        PMID: 17852105     DOI: 10.1080/02688690701449251

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  31 in total

1.  Thymidine kinase gene delivery using curcumin loaded peptide micelles as a combination therapy for glioblastoma.

Authors:  Jin Hyeong Park; Jaesik Han; Minhyung Lee
Journal:  Pharm Res       Date:  2014-08-27       Impact factor: 4.200

2.  Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection.

Authors:  Kaisorn L Chaichana; Matthew J McGirt; James Frazier; Frank Attenello; Hugo Guerrero-Cazares; Alfredo Quinones-Hinojosa
Journal:  J Neurooncol       Date:  2008-05-06       Impact factor: 4.130

3.  Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma.

Authors:  Lola B Chambless; Scott L Parker; Laila Hassam-Malani; Matthew J McGirt; Reid C Thompson
Journal:  J Neurooncol       Date:  2011-08-11       Impact factor: 4.130

4.  Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients.

Authors:  Guo-Bin Zhang; Xiang-Li Cui; Da-Li Sui; Xiao-Hui Ren; Zhe Zhang; Zhong-Cheng Wang; Song Lin
Journal:  J Neurooncol       Date:  2013-03-15       Impact factor: 4.130

5.  Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article.

Authors:  Kaisorn L Chaichana; Aditya N Halthore; Scott L Parker; Alessandro Olivi; Jon D Weingart; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  J Neurosurg       Date:  2010-06-04       Impact factor: 5.115

6.  The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme.

Authors:  Lola B Chambless; Heather M Kistka; Scott L Parker; Laila Hassam-Malani; Matthew J McGirt; Reid C Thompson
Journal:  J Neurooncol       Date:  2014-10-26       Impact factor: 4.130

Review 7.  Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.

Authors:  Kaisorn L Chaichana; Leon Pinheiro; Henry Brem
Journal:  Ther Deliv       Date:  2015-03

Review 8.  The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors.

Authors:  Roy E Strowd; Stuart A Grossman
Journal:  Curr Treat Options Oncol       Date:  2015-08

9.  Changes in caregiver perceptions over time in response to providing care for a loved one with a primary malignant brain tumor.

Authors:  Allison Hricik; Heidi Donovan; Sarah E Bradley; Barbara A Given; Catherine M Bender; Alyssa Newberry; Rebekah Hamilton; Charles W Given; Paula Sherwood
Journal:  Oncol Nurs Forum       Date:  2011-03       Impact factor: 2.172

10.  Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients.

Authors:  Mohamad A Salkeni; Ahmad Zarzour; Tracy Y Ansay; Christopher M McPherson; Ronald E Warnick; Olivier Rixe; El Mustapha Bahassi
Journal:  J Neurooncol       Date:  2013-07-23       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.